Alto Neuroscience (NYSE:ANRO) Shares Up 10% – Still a Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) was up 10% on Tuesday . The company traded as high as $18.42 and last traded at $18.5850. Approximately 114,874 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 206,278 shares. The stock had previously closed at $16.89.

Analyst Ratings Changes

Several research firms have weighed in on ANRO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. HC Wainwright lifted their price target on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Robert W. Baird raised their price target on Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Chardan Capital upped their price target on shares of Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Finally, BTIG Research raised their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $26.50.

Alto Neuroscience Trading Up 8.3%

The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The firm has a fifty day simple moving average of $17.14 and a 200-day simple moving average of $11.05. The firm has a market cap of $609.90 million, a P/E ratio of -8.57 and a beta of 2.78.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can purchased a new position in shares of Alto Neuroscience during the second quarter valued at about $25,000. Ground Swell Capital LLC bought a new stake in Alto Neuroscience in the second quarter worth about $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Alto Neuroscience during the second quarter valued at approximately $33,000. AlphaCore Capital LLC raised its holdings in shares of Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares during the period. Finally, AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience during the 1st quarter worth approximately $52,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.